Brasada Capital Management LP Acquires New Shares in Stryker Corporation $SYK

Brasada Capital Management LP bought a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,330 shares of the medical technology company’s stock, valued at approximately $734,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Gables Capital Management Inc. acquired a new position in Stryker during the 2nd quarter worth approximately $25,000. Kilter Group LLC acquired a new stake in Stryker in the second quarter valued at approximately $25,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the fourth quarter worth $26,000. Sankala Group LLC bought a new stake in shares of Stryker during the fourth quarter worth $26,000. Finally, Compass Financial Management LLC acquired a new position in shares of Stryker during the second quarter worth $27,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Performance

NYSE SYK opened at $322.20 on Friday. The company has a market capitalization of $123.58 billion, a price-to-earnings ratio of 33.39, a PEG ratio of 2.10 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The stock has a fifty day simple moving average of $328.64 and a 200 day simple moving average of $331.47.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Leerink Partners dropped their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Canaccord Genuity Group lowered their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Citigroup reiterated a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. Sanford C. Bernstein set a $410.00 price target on Stryker in a research note on Friday, May 1st. Finally, Piper Sandler reduced their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.